Hypoxia-inducible factor 1α determines gastric cancer chemosensitivity via modulation of p53 and Nf-κB

PLoS ONE

Volumn 5, Issue 8, 2010, Pages

  Rohwer, Nadine ^a,b   Dame, Christof ^a   Haugstetter, Anja ^a,c   Wiedenmann, Bertram ^a   Detjen, Katharina ^a   Schmitt, Clemens A ^a,c   Cramer, Thorsten ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P21; PROTEIN P53; REACTIVE OXYGEN METABOLITE; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR RELA; HIF1A PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER THERAPY; CELL AGING; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; GENOTOXICITY; HUMAN; HUMAN CELL; PHENOTYPE; PROTEIN DEPLETION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STOMACH CANCER; WESTERN BLOTTING; CELL CYCLE; DRUG EFFECT; DRUG RESISTANCE; GENE SILENCING; GENETICS; METABOLISM; MUTATION; PATHOLOGY; STOMACH TUMOR; TUMOR CELL LINE;

APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GENE KNOCKDOWN TECHNIQUES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MUTATION; REACTIVE OXYGEN SPECIES; STOMACH NEOPLASMS; TRANSCRIPTION FACTOR RELA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77957786826     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012038     Document Type: Article

References (55)

1. Gatti L, Zunino F (2005) Overview of tumor cell chemoresistance mechanisms. Methods Mol Med 111: 127-148.
2. Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627.
3. Morin PJ (2003) Drug resistance and the microenvironment: nature and nurture. Drug Resist Updat 6: 169-172.
4. Chabner BA, Roberts TG (2005) Chemotherapy and the war on cancer. Nat Rev Cancer 5: 65-72.
5. Wilson TR, Longley DB, Johnston PG (2006) Chemoresistance in solid tumours. Ann Oncol 17: 315-324.
6. Brown LM, Cowen RL, Debray C, Eustace A, Erler JT, et al. (2006) Reversing Hypoxic Cell Chemoresistance in Vitro Using Genetic and Small Molecule Approaches Targeting Hypoxia Inducible Factor-1. Mol Pharmacol 69: 411-418.
7. Sullivan R, Pare GC, Frederiksen LJ, Semenza GL, Graham CH (2008) Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity. Mol Cancer Ther 7: 1961-1973.
8. Unruh A, Ressel A, Mohamed HG, Johnson RS, Nadrowitz R, et al. (2003) The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 22: 3213-3220.
9. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732.
10. Frede S, Berchner-Pfannschmidt U, Fandrey J (2007) Regulation of hypoxia-inducible factors during inflammation. Methods Enzymol 435: 405-419.
11. Weidemann A, Johnson RS (2008) Biology of HIF-1[alpha]. Cell Death Differ 15: 621-627.
12. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, et al. (2000) Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 60: 4693-4696.
13. Bos R, van der GP, Greijer AE, Shvarts A, Meijer S, et al. (2003) Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97: 1573-1581.
14. Kurokawa T, Miyamoto M, Kato K, Cho Y, Kawarada Y, et al. (2003) Overexpression of hypoxia-inducible-factor 1alpha(HIF-1alpha) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Br J Cancer 89: 1042-1047.
15. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, et al. (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59: 5830-5835.
16. Patiar S, Harris AL (2006) Role of hypoxia-inducible factor-1alpha as a cancer therapy target. Endocr Relat Cancer 13: 61-75.
17. Hao J, Song X, Song B, Liu Y, Wei L, et al. (2008) Effects of lentivirus-mediated HIF-1alpha knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells. Cancer Gene Ther 15: 449-455.
18. Liu L, Ning X, Sun L, Zhang H, Shi Y, et al. (2008) Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci 99: 121-128.
19. Nardinocchi L, Puca R, Sacchi A, D'Orazi G (2009) Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis. Mol Cancer 8: 1.
20. Sasabe E, Zhou X, Li D, Oku N, Yamamoto T, et al. (2007) The involvement of hypoxia-inducible factor-1alpha in the susceptibility to gamma-rays and chemotherapeutic drugs of oral squamous cell carcinoma cells. Int J Cancer 120: 268-277.
21. Liu L, Ning X, Sun L, Shi Y, Han S, et al. (2007) Involvement of MGr1-Ag/37LRP in the vincristine-induced HIF-1 expression in gastric cancer cells. Mol Cell Biochem 303: 151-160.
22. Rohwer N, Welzel M, Daskalow K, Pfander D, Wiedenmann B, et al. (2008) Hypoxia-inducible factor 1alpha mediates anoikis resistance via suppression of alpha5 integrin. Cancer Res 68: 10113-10120.
23. Schmitt CA (2003) Senescence, apoptosis and therapy-cutting the lifelines of cancer. Nat Rev Cancer 3: 286-295.
24. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, et al. (2002) Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8: 282-288.
25. Cusack JC Jr, Liu R, Baldwin AS Jr (2000) Inducible Chemoresistance to 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin(CPT-11) in Colorectal Cancer Cells and a Xenograft Model Is Overcome by Inhibition of Nuclear Factor-{kappa}B Activation. Cancer Res 60: 2323-2330.
26. Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ, et al. (2001) Enhanced Chemosensitivity to CPT-11 with Proteasome Inhibitor PS-341:: Implications for Systemic Nuclear Factor-{{kappa}}B Inhibition. Cancer Res 61: 3535-3540.
27. Wang CY, Cusack JC Jr, Liu R, Baldwin AS Jr (1999) Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 5: 412-417.
28. Martindale JL, Holbrook NJ (2002) Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol 192: 1-15.
29. Zhang H, Gao P, Fukuda R, Kumar G, Krishnamachary B, et al. (2007) HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 11: 407-420.
30. Zhang H, Bosch-Marce M, Shimoda LA, Tan YS, Baek JH, et al. (2008) Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem 283: 10892-10903.
31. Nakamura J, Kitajima Y, Kai K, Mitsuno M, Ide T, et al. (2009) Hypoxia-inducible factor-1alpha expression predicts the response to 5-fluorouracil-based adjuvant chemotherapy in advanced gastric cancer. Oncol Rep 22: 693-699.
32. Welford SM, Bedogni B, Gradin K, Poellinger L, Broome PM, et al. (2006) HIF1alpha delays premature senescence through the activation of MIF. Genes Dev 20: 3366-3371.
33. Harris SL, Levine AJ (2005) The p53 pathway: positive and negative feedback loops. Oncogene 24: 2899-2908.
34. Vazquez A, Bond EE, Levine AJ, Bond GL (2008) The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 7: 979-987.
35. Hammond EM, Giaccia AJ (2006) Hypoxia-inducible factor-1 and p53: friends, acquaintances, or strangers? Clin Cancer Res 12: 5007-5009.
36. Wirthner R, Wrann S, Balamurugan K, Wenger RH, Stiehl DP (2008) Impaired DNA double-strand break repair contributes to chemoresistance in HIF-1 alpha-deficient mouse embryonic fibroblasts. Carcinogenesis 29: 2306-2316.
37. Goda N, Ryan HE, Khadivi B, McNulty W, Rickert RC, et al. (2003) Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia. Mol Cell Biol 23: 359-369.
38. Ravi R, Mookerjee B, van HY, Bedi GC, Giordano A, et al. (1998) p53-mediated repression of nuclear factor-kappaB RelA via the transcriptional integrator p300. Cancer Res 58: 4531-4536.
39. Culmsee C, Siewe J, Junker V, Retiounskaia M, Schwarz S, et al. (2003) Reciprocal inhibition of p53 and nuclear factor-kappaB transcriptional activities determines cell survival or death in neurons. J Neurosci 23: 8586-8595.
40. Nakanishi C, Toi M (2005) Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5: 297-309.
41. Belaiba RS, Bonello S, Zahringer C, Schmidt S, Hess J, et al. (2007) Hypoxia up-regulates hypoxia-inducible factor-1alpha transcription by involving phosphatidylinositol 3-kinase and nuclear factor kappaB in pulmonary artery smooth muscle cells. Mol Biol Cell 18: 4691-4697.
42. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, et al. (2008) NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 453: 807-811.
43. Walmsley SR, Print C, Farahi N, Peyssonnaux C, Johnson RS, et al. (2005) Hypoxia-induced neutrophil survival is mediated by HIF-1alpha-dependent NF-kappaB activity. J Exp Med 201: 105-115.
44. Karin M (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436.
45. Holley AK, St Clair DK (2009) Watching the watcher: regulation of p53 by mitochondria. Future Oncol 5: 117-130.
46. Liu Y, Fiskum G, Schubert D (2002) Generation of reactive oxygen species by the mitochondrial electron transport chain. J Neurochem 80: 780-787.
47. Kim JW, Tchernyshyov I, Semenza GL, Dang CV (2006) HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3: 177-185.
48. Archer SL, Gomberg-Maitland M, Maitland ML, Rich S, Garcia JG, et al. (2008) Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer. Am J Physiol Heart Circ Physiol 294: H570-H578.
49. Bertout JA, Majmundar AJ, Gordan JD, Lam JC, Ditsworth D, et al. (2009) HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. Proc Natl Acad Sci U S A 106: 14391-14396.
50. Tormos KV, Chandel NS (2010) Inter-connection between mitochondria and HIFs. J Cell Mol Med 14: 795-804.
51. Roberts AM, Watson IR, Evans AJ, Foster DA, Irwin MS, et al. (2009) Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells. Cancer Res 69: 9056-9064.
52. Plath T, Detjen K, Welzel M, von MZ, Murphy D, et al. (2000) A novel function for the tumor suppressor p16(INK4a): induction of anoikis via upregulation of the alpha(5)beta(1) fibronectin receptor. J Cell Biol 150: 1467-1478.
53. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, et al. (2002) A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109: 335-346.
54. Cramer T, Juttner S, Plath T, Mergler S, Seufferlein T, et al. (2008) Gastrin transactivates the chromogranin A gene through MEK-1/ERK- and PKC-dependent phosphorylation of Sp1 and CREB. Cell Signal 20: 60-72.
55. Dame C, Sola MC, Lim KC, Leach KM, Fandrey J, et al. (2004) Hepatic erythropoietin gene regulation by GATA-4. J Biol Chem 279: 2955-2961.